# A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women

> **NCT03270969** · PHASE1 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 15 (actual)

## Conditions studied

- HIV Prevention

## Interventions

- **DRUG:** Tenofovir Disoproxil Fumarate/Emtricitabine

## Key facts

- **NCT ID:** NCT03270969
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-05
- **Primary completion:** 2018-09-10
- **Final completion:** 2018-09-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03270969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03270969, "A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03270969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*